Systematic review: The lower gastrointestinal adverse effects of non-steroidal anti-inflammatory drugs

Alimentary Pharmacology and Therapeutics

Volumn 24, Issue 5, 2006, Pages 751-767

  Laine, L ^a   Smith, R ^b   Min, K ^b   Chen, C ^c   Dubois, R W ^b  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b CERNER CORPORATION   (United States)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; IBUPROFEN; INDOMETACIN; MELOXICAM; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PLACEBO; ROFECOXIB;

ANALGESIA; CLINICAL TRIAL; DIVERTICULOSIS; GASTROINTESTINAL ENDOSCOPY; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HEMATOCHEZIA; HUMAN; INTESTINE INJURY; INTESTINE MUCOSA; INTESTINE MUCOSA BREAK; INTESTINE MUCOSA PERMEABILITY; INTESTINE PERFORATION; INTESTINE ULCER; META ANALYSIS; OCCULT BLOOD; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; STATISTICAL SIGNIFICANCE; STOMACH EROSION; SYSTEMATIC REVIEW;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE 2 INHIBITORS; DIVERTICULUM; GASTROINTESTINAL HEMORRHAGE; HUMANS; INFLAMMATION; INTESTINAL DISEASES; INTESTINE, LARGE; INTESTINE, SMALL; LOWER GASTROINTESTINAL TRACT; PERMEABILITY;

EID: 33747350734     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2006.03043.x     Document Type: Review

References (61)

1. Cryer B. NSAID-associated deaths: the rise and fall of NSAID-associated GI mortality. Am J Gastroenterol 2005; 100: 1694-5.
2. Laine L. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient. Gastroenterology 2001; 120: 594-606.
3. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med 1999; 340: 1888-99.
4. Longstreth GF. Epidemiology and outcome of patients hospitalized with acute lower gastrointestinal hemorrhage: a population-based study. Am J Gastroenterol 1997; 92: 419-24.
5. Lanas A, Perez-Aisa MA, Feu F, et al. A nationwide study of mortality associated with hospital admission due to severe gastrointestinal events and those associated with nonsteroidal antiinflammatory drug use. Am J Gastroenterol 2005; 100: 1685-93.
6. Laine L, Harper S, Simon T, et al. A randomized trial comparing the effect of rofecoxib, a cyclooxygenase 2-specific inhibitor, with that of ibuprofen on the gastroduodenal mucosa of patients with osteoarthritis.Rofecoxib Osteoarthritis Endoscopy Study Group. Gastroenterology 1999; 117: 776-83.
7. Simon LS, Weaver AL, Graham DY, et al. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized controlled trial. JAMA 1999; 282: 1921-8.
8. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 2000; 343: 1520-8.
9. Schnitzer TJ, Burmester GR, Mysler E, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), reduction in ulcer complications: randomised controlled trial. Lancet 2004; 364: 665-74.
10. Maiden L, Thjodleifsson B, Theodors A, Gonzalez J, Bjarnason I. A quantitative analysis of NSAID-induced small bowel pathology by capsule enteroscopy. Gastroenterology 2005; 128: 1172-8.
11. Goldstein JL, Eisen GM, Lewis B, et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol 2005; 3: 133-41.
12. Graham DY, Opekun AR, Willingham FF, Qureshi WA. Visible small-intestinal mucosal injury in chronic NSAID users. Clin Gastroenterol Hepatol 2005; 3: 55-9.
13. Mpofu S, Mpofu CM, Hutchinson D, et al. Steroids, non-steroidal antiinflammatory drugs, and sigmoid diverticular abscess perforation in rheumatic conditions. Ann Rheum Dis 2004; 63: 588-90.
14. Atherton C, Jones J, McKaig B, et al. Pharmacology and gastrointestinal safety of lumiracoxib, a novel cyclooxygenase-2 selective inhibitor: an integrated study. Clin Gastroenterol Hepatol 2004; 2: 113-20.
15. Morris CR, Harvey IM, Stebbings WS, et al. Anti-inflammatory drugs, analgesics and the risk of perforated colonic diverticular disease. Br J Surg 2003; 90: 1267-72.
16. Suenaert P, Bulteel V, Den Hond E, et al. In vivo influence of nicotine on human basal and NSAID-induced gut barrier function. Scand J Gastroenterol 2003; 38: 399-408.
17. Laine L, Connors LG, Reicin A, et al. Serious lower gastrointestinal clinical events with nonselective NSAID or coxib use. Gastroenterology 2003; 124: 288-92.
18. Goh H, Bourne R. Non-steroidal anti-inflammatory drugs and perforated diverticular disease: a case-control study. Ann R Coll Surg Engl 2002; 84: 93-6.
19. Kaplan RC, Heckbert SR, Psaty BM. Risk factors for hospitalized upper or lower gastrointestinal tract bleeding in treated hypertensives. Prev Med 2002; 34: 455-62.
20. Smecuol E, Bai JC, Sugai E, et al. Acute gastrointestinal permeability responses to different non-steroidal anti-inflammatory drugs. Gut 2001; 49: 650-5.
21. Twiss IM, Burggraaf J, Schoemaker RC, et al. The sugar absorption test in the evaluation of the gastrointestinal intolerance to bisphosphonates: studies with oral pamidronate. Clin Pharmacol Ther 2001; 69: 431-7.
22. Catanoso M, Lo GR, Giofre MR, et al. Gastro-intestinal permeability is increased in patients with limited systemic sclerosis. Scand J Rheumatol 2001; 30: 77-81.
23. Shah AA, Thjodleifsson B, Murray FE, et al. Selective inhibition of COX-2 in humans is associated with less gastrointestinal injury: a comparison of nimesulide and naproxen. Gut 2001; 48: 339-46.
24. Yocum D, Fleischmann R, Dalgin P, et al. Safety and efficacy of meloxicam in the treatment of osteoarthritis: a 12-week, double-blind, multiple-dose, placebo-controlled trial. The Meloxicam Osteoarthritis Investigators. Arch Intern Med 2000; 160: 2947-54.
25. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 2000; 284: 1247-55.
26. Smetanka RD, Lambert GP, Murray R, et al. Intestinal permeability in runners in the 1996 Chicago marathon. Int J Sport Nutr 1999; 9: 426-33.
27. Cryer B, Feldman M. Effects of very low dose daily, long-term aspirin therapy on gastric, duodenal, and rectal prostaglandin levels and on mucosal injury in healthy humans. Gastroenterology 1999; 117: 17-25.
28. Doyle G, Furey S, Berlin R, et al. Gastrointestinal safety and tolerance of ibuprofen at maximum over-the-counter dose. Aliment Pharmacol Ther 1999; 13: 897-906.
29. Aldoori WH, Giovannucci EL, Rimm EB, Wing AL, Willett WC. Use of acetaminophen and nonsteroidal anti-inflammatory drugs: a prospective study and the risk of symptomatic diverticular disease in men. Arch Fam Med 1998; 7: 255-60.
30. Peura DA, Lanza FL, Gostout CJ, Foutch PG. The American College of Gastroenterology Bleeding Registry: preliminary findings. Am J Gastroenterol 1997; 92: 924-8.
31. Wilcox CM, Alexander LN, Cotsonis GA, Clark WS. Nonsteroidal antiinflammatory drugs are associated with both upper and lower gastrointestinal bleeding. Dig Dis Sci 1997; 42: 990-7.
32. Lanas A, Serrano P, Bajador E, et al. Evidence of aspirin use in both upper and lower gastrointestinal perforation. Gastroenterology 1997; 112: 683-9.
33. Kremer JM, Malamood H, Maliakkal B, et al. Fish oil dietary supplementation for prevention of indomethacin induced gastric and small bowel toxicity in healthy volunteers. J Rheumatol 1996; 23: 1770-3.
34. Day JP, Lanas A, Rustagi P, Hirschowitz BI. Reversible prolonged skin bleeding time in acute gastrointestinal bleeding presumed due to NSAIDs. J Clin Gastroenterol 1996; 22: 96-103.
35. Choi VM, Coates JE, Chooi J, Thomson AB, Russell AS. Small bowel permeability-a variable effect of NSAIDS. Clin Invest Med 1995; 18: 357-61.
36. Slattery J, Warlow CP, Shorrock CJ, Langman MJ. Risks of gastrointestinal bleeding during secondary prevention of vascular events with aspirin-analysis of gastrointestinal bleeding during the UK-TIA trial. Gut 1995; 37: 509-11.
37. Holt S, Rigoglioso V, Sidhu M, et al. Nonsteroidal antiinflammatory drugs and lower gastrointestinal bleeding. Dig Dis Sci 1993; 38: 1619-23.
38. Allison MC, Howatson AG, Torrance CJ, Lee FD, Russell RI. Gastrointestinal damage associated with the use of non-steroidal antiinflammatory drugs. N Engl J Med 1992; 327: 749-54.
39. Bjarnason I, Smethurst P, Macpherson A, et al. Glucose and citrate reduce the permeability changes caused by indomethacin in humans. Gastroenterology 1992; 102: 1546-50.
40. Morris AJ, Howden CW, Robertson C, et al. Increased intestinal permeability in ankylosing spondylitis-primary lesion or drug effect? Gut 1991; 32: 1470-2.
41. Bjarnason I, Smethurst P, Levi AJ, Menzies IS, Peters TJ. The effect of polyacrylic acid polymers on small-intestinal function and permeability changes caused by indomethacin. Scand J Gastroenterol 1991; 26: 685-8.
42. Bjarnason I, Fehilly B, Smethurst P, Menzies IS, Levi AJ. Importance of local versus systemic effects of non-steroidal anti-inflammatory drugs in increasing small intestinal permeability in man. Gut 1991; 32: 275-7.
43. Campbell K, Steele RJ. Non-steroidal anti-inflammatory drugs and complicated diverticular disease: a case-control study. Br J Surg 1991; 78: 190-1.
44. Jenkins AP, Trew DR, Crump BJ, et al. Do non-steroidal anti-inflammatory drugs increase colonic permeability? Gut 1991; 32: 66-9.
45. Simenon G, Van Gossum A, Adler M, Rickaert F, Appelboom T. Macroscopic and microscopic gut lesions in seronegative spondyloarthropathies. J Rheumatol 1990; 17: 1491-4.
46. Wilson RG, Smith AN, Macintyre IM. Complications of diverticular disease and non-steroidal anti-inflammatory drugs: a prospective study. Br J Surg 1990; 77: 1103-4.
47. Aabakken L, Bjornbeth BA, Weberg R, et al. NSAID-associated gastroduodenal damage: does famotidine protection extend into the mid- and distal duodenum? Aliment Pharmacol Ther 1990; 4: 295-303.
48. Bjarnason I, Smethurst P, Fenn CG, et al. Misoprostol reduces indomethacin-induced changes in human small intestinal permeability. Dig Dis Sci 1989; 34: 407-11.
49. Bjarnason I, Smethurst P, Clark P, et al. Effect of prostaglandin on indomethacin-induced increased intestinal permeability in man. Scand J Gastroenterol Suppl 1989; 164: 97-102.
50. Bjarnason I, Williams P, Smethurst P, Peters TJ, Levi AJ. Effect of non-steroidal anti-inflammatory drugs and prostaglandins on the permeability of the human small intestine. Gut 1986; 27: 1292-7.
51. Rampton DS, Barton TP. Are prostaglandins cytoprotective in the human large intestine? The effect of indomethacin on rectal mucosal function and prostaglandin E2 release in vivo. Agents Actions 1984; 14: 715-8.
52. Sigthorsson G, Crane R, Simon T, et al. COX-2 inhibition with rofecoxib does not increase intestinal permeability in healthy subjects: a double blind crossover study comparing rofecoxib with placebo and indomethacin. Gut 2000; 47: 527-32.
53. Lanas A, Sekar MC, Hirschowitz BI. Objective evidence of aspirin use in both ulcer and nonulcer upper and lower gastrointestinal bleeding. Gastroenterology 1992; 103: 862-9.
54. Langman MJ, Morgan L, Worrall A. Use of anti-inflammatory drugs by patients admitted with small or large bowel perforations and haemorrhage. Br Med J (Clin Res Ed) 1985; 290: 347-9.
55. Mielants H, Goemaere S, De Vos M, et al. Intestinal mucosal permeability in inflammatory rheumatic diseases: I. Role of antiinflammatory drugs. J Rheumatol 1991; 18: 389-93.
56. Laine L, Maller ES, Yu C, Quan H, Simon T. Ulcer formation with low-dose enteric-coated aspirin and the effect of COX-2 selective inhibition: a double-blind trial. Gastroenterology 2004; 127: 395-402.
57. Lanas A, Bajador E, Serrano P, et al. Nitrovasodilators, low-dose aspirin, other nonsteroidal antiinflammatory drugs, and the risk of upper gastrointestinal bleeding. N Engl J Med 2000; 343: 834-9.
58. Longstreth GF. Epidemiology of hospitalization for acute upper gastrointestinal hemorrhage: a population-based study. Am J Gastroenterol 1995; 90: 206-10.
59. Singh G, Rosen RD. NSAID induced gastrointestinal complications: the ARAMIS perspective-1997. Arthritis, Rheumatism, and Aging Medical Information System. J Rheumatol Suppl 1998; 51: 8-16.
60. Bicknell SG, Brown JA, Walker BA, Amar JN. Nonsteroidal anti-inflammatory drug-induced colonic stricture: case report. Abdom Imaging 2002; 27: 731-3.
61. Eis MJ, Watkins BM, Philip A, Welling RE. Nonsteroidal-induced benign strictures of the colon: a case report and review of the literature. Am J Gastroenterol 1998; 93: 120-1.